Avrobio

Azadeh Golipour, Chief Technology Officer 

Cambridge, MA 

(NASDAQ: AVRO) 

Virtual Presentation 

AVROBIO’s vision is to bring personalized gene therapy to the world. We aim to prevent, halt, or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle, and bone. AVROBIO’s pipeline is powered by our industry-leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. It includes clinical programs in cystinosis and Gaucher disease type 1, as well as preclinical programs in Gaucher disease type 3, Hunter syndrome, and Pompe disease. 

www.avrobio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions